WHAT IS CLAIMED IS:

1. A compound of the formula I:

Ι

wherein:

5

B is a bicycloheterocycle selected from the group consisting of:

where T, U, V, W, X and Y are each independently a carbon atom or a nitrogen atom wherein no more than two of T, U, V and W, and no more than three of T, U, V, W, X and Y, are a nitrogen atom,

where B is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^1 , R^2 , R^{3a} and R^{3b} , wherein

 R^1 , R^2 , R^{3a} and R^{3b} are independently selected from:

- (1) -C₁-6alkyl, which is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:
 - (a) halo,
 - (b) hydroxy,
 - (c) -O-C₁₋₆alkyl,
 - (d) -C3-6cycloalkyl,

(e) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, or morpholinyl,

which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

- (i) -C₁-6alkyl,
- (ii) -O-C₁₋₆alkyl,
- (iii) halo,
- (iv) hydroxy,
- (v) trifluoromethyl, and
- (vi) -OCF₃,
- (f) -CO₂R⁹, wherein R⁹ is independently selected from:
 - (i) hydrogen,
 - (ii) -C₁-6alkyl, which is unsubstituted or substituted with 1-6 fluoro,
 - (iii) -C₃-6cycloalkyl,
 - (iv) benzyl, and
 - (v) phenyl,
- (g) -NR10R11, wherein R10 and R11 are independently selected from:
 - (i) hydrogen,
 - (ii) -C₁-6alkyl, which is unsubstituted or substituted with 1-6 fluoro,
 - (iii) -C5-6cycloalkyl.
 - (iv) benzyl,
 - (v) phenyl,
 - (vi) -COR9, and

15

10

5

20

25

30

(vii) -SO₂R₁₂, -SO₂R¹², wherein R^{12} is independently selected from: (h) -C₁-6alkyl, which is unsubstituted or substituted with 1-6 fluoro, (i) (ii) -C5-6cycloalkyl, 5 (iii) benzyl, and (iv) phenyl, -CONR10aR11a, wherein R10a and R11a are independently selected (i) from: (i) hydrogen, 10 -C1-6alkyl, which is unsubstituted or substituted with 1-6 fluoro, (ii) (iii) -C5-6cycloalkyl, (iv) benzyl, (v) phenyl, or where R10a and R11a may be joined together to form a ring selected 15 from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from: **(I)** -C₁₋₆alkyl (II)-O-C₁₋₆alkyl 20 (III)halo (IV) hydroxy (V) phenyl, and (VI) benzyl, trifluoromethyl, (j) 25 (k) -OCO₂R⁹, -(NR10a)CO2R9, (l) (m) -O(CO)NR10aR11a -(NR9)(CO)NR10aR11a, and (n) (o) -O-C3-6cycloalkyl, 30 -C3-6cycloalkyl, which is unsubstituted or substituted with 1-7 substituents where (2) the substituents are independently selected from: (a) halo, (b) hydroxy,

(c)

-O-C₁₋₆alkyl,

- (d) trifluoromethyl,
- phenyl, which is unsubstituted or substituted with 1-5 substituents where (e) the substituents are independently selected from:
 - (i) -C₁₋₆alkyl,
 - (ii) -O-C₁₋₆alkyl,
 - (iii) halo.
 - (iv) hydroxy, and
 - (v) trifluoromethyl,
- phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, (3) pyrazinyl, thienyl, pyridazinyl, pyrrolidinyl, azetidinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, tetrazolyl, azepinyl, benzimidazolyl, benzopyranyl, benzofuryl, benzothiazolyl, benzoxazolyl, chromanyl, furyl, imidazolinyl, indolinyl, indolyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, isoindolinyl, tetrahydroisoquinolinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2oxopyrrolidinyl, pyrazolidinyl, pyrazolyl, pyrrolyl, quinazolinyl, tetrahydrofuryl, thiazolinyl, purinyl, naphthyridinyl, quinoxalinyl, 1,3-dioxolanyl, oxadiazolyl, piperidinyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydrothiopyranyl, and morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
 - -C1-6alkyl, which is unsubstituted or substituted with 1-6 fluoro, (a)
 - (b) halo.
 - (c) hydroxy.
 - -O-C1-6alkyl, which is unsubstituted or substituted with 1-6 fluoro, (d)
 - (e) -C3-6cycloalkyl,
 - phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, (f) pyrimidinyl, pyrazinyl, thienyl, or morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
 - (i) -C₁₋₆alkyl,
 - (ii) -O-C₁₋₆alkyl,
 - (iii) halo,
 - (iv) hydroxy, and
 - (v) trifluoromethyl,
 - -CO₂R⁹, (g)

30

25

5

10

15

20

```
(h)
                                -(CO)R^9
                                -NR10R11
                        (i)
                        (j)
                                -CONR10R11
                        (k)
                               охо
   5
                               -SR12.
                        (1)
                               -S(O)R12, and
                        (m)
                               -SO<sub>2</sub>R<sub>12</sub>,
                       (n)
                (4)
                       halo,
                (5)
                       oxo,
  10
                (6)
                       hydroxy,
                       -O-C<sub>1</sub>-6alkyl, which is unsubstituted or substituted with 1-5 halo,
               (7)
               (8)
                       -CN,
               (9)
                       -CO_2R^9
               (10)
                       -NR10R11
 15
               (11)
                       -SO_2R12
               (12)
                      -CONR10aR11a
               (13)
                      -OCO_2R^9,
               (14)
                      -(NR 10a)CO2R9
               (15)
                      -O(CO)NR10aR11a
20
                      -(NR<sup>9</sup>)(CO)NR10aR11a
              (16)
                      -(CO)-(CO)NR10aR11a, and
              (17)
              (18)
                      -(CO)-(CO)OR9;
              or where R^{3a} and R^{3b} and the carbon atom(s) to which they are attached may be joined
                      together to form a ring selected from cyclobutyl, cyclopentyl, cyclohexyl,
25
                      cyclopentenyl, cyclohexenyl, azetidinyl, pyrrolidinyl, piperidinyl,
                      tetrahydrofuranyl, tetrahydropyranyl, furanyl, dihydrofuranyl, dihydropyranyl,
                     thienyl, dihydrothienyl, tetrahydrothienyl, dihydrothiopyranyl,
                     tetrahydrothiopyranyl or piperazinyl, which is unsubstituted or substituted with 1-
                     5 substituents where the substituents are independently selected from:
30
                             -C<sub>1</sub>-6alkyl, which is unsubstituted or substituted with 1-3 substituents
                     (a)
                             where the substituents are independently selected from:
                             (i)
                                    halo,
                             (ii)
                                    hydroxy,
```

(iii)

-O-C₁₋₆alkyl,

(iv) -C3-6cycloalkyl, phenyl or heterocycle, wherein heterocycle is selected from: (v) pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, or morpholinyl, which is 5 unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from: **(I)** -C₁₋₆alkyl, (II)-O-C₁₋₆alkyl, (III) halo, 10 (TV) hydroxy, (V) trifluoromethyl, and (VI) -OCF₃, -CO₂R⁹, (vi) (vii) -NR10R11 15 (viii) -SO₂R₁₂, -CONR10aR11a, and (ix) -(NR10a)CO2R9, (x) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, (b) pyrimidinyl, pyrazinyl, thienyl, pyridazinyl, pyrrolidinyl, azetidinyl, 20 piperidinyl and morpholinyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: -C1-6alkyl, which is unsubstituted or substituted with 1-6 fluoro, (i) (ii) halo, (iii) hydroxy, 25 -O-C1-6alkyl, which is unsubstituted or substituted with 1-6 (iv) fluoro, and (v) -C3-6cycloalkyl, (c) halo, (d) -SO₂R¹², 30 (e) hydroxy, -O-C₁-6alkyl, which is unsubstituted or substituted with 1-5 halo, (f) (g) -CN, (h) -COR 12, (i) -NR10R11

(j) -CONR10aR11a (k) $-CO_2R^9$ **(l)** -(NR10a)CO2R9, -O(CO)NR10aR11a (m) 5 -(NR9)(CO)NR10aR11a, and (n) (o) oxo; A^1 and A^2 are independently selected from: (1) a bond, -CR 13 R 14 -, wherein R 13 and R 14 are independently selected from: 10 (2) (a) C₁₋₆ alkyl, which is unsubstituted or substituted with 1-6 fluoro, and (b) (c) hydroxy, or wherein one of A¹ and A² is absent; 15 R⁴ is selected from: (1) hydrogen, C₁₋₆ alkyl, which is unsubstituted or substituted with 1-6 fluoro, (2) (3) C₅₋₆ cycloalkyl, 20 (4) benzyl, and (5) phenyl; R^{5a} , R^{5b} and R^{5c} are independently selected from: (1) hydrogen, 25 (2) C₁₋₆ alkyl, -O-C₁₋₆alkyl, (3) (4) -OCF₃, trifluoromethyl, (5) (6) halo, 30 **(7)** hydroxy, and (8) -CN;

 R^6 is selected from:

(1) hydrogen,

	(2)	-C	6alkyl or -C3-60	cycloalkyl which are unsubstituted or substituted with 1.7	
		sub	tituents where th	le substituents are independently sologied 5	
		(a)	halo,	made independently selected from:	
		(b)	hydroxy,		
5		(c)	-O-C ₁₋₆ alkyl	,	
		(d)	-C3-6cycloall	cyl,	
		(e)	(e) phenyl, which is unsubstituted or substituted with 1.5 substituted		
			the substituen	ts are independently selected from:	
10			(i) -C ₁₋₆ 8	alkyl,	
10			(ii) -O-C ₁	-6alkyl,	
			(iii) halo,		
			(iv) hydrox	y, and	
		(b) hydroxy, (c) -O-C1-6alkyl, (d) -C3-6cycloalkyl, (e) phenyl, which is unsubstituted or substituted with 1-5 substituents when the substituents are independently selected from: (i) -C1-6alkyl, (ii) -O-C1-6alkyl, (iii) halo, (iv) hydroxy, and (v) trifluoromethyl, (f) -CO2R9, (g) -NR10R11, (h) -CONR10R11, (i) -SO2R12, and (j) trifluoromethyl phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl pyrazinyl, thienyl, or morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from: (a) -C1-6alkyl, (b) -O-C1-6alkyl, (c) halo, (d) hydroxy, and (e) trifluoromethyl;			
		(f)			
15			•		
				•	
		-			
20	(3)	phen	(a) halo, (b) hydroxy, (c) -O-C1-6alkyl, (d) -C3-6cycloalkyl, (e) phenyl, which is unsubstituted or substituted with 1-5 substituents wh the substituents are independently selected from: (i) -C1-6alkyl, (ii) -O-C1-6alkyl, (iii) halo, (iv) hydroxy, and (v) trifluoromethyl, (f) -CO2R9, (g) -NR10R11, (h) -CONR10R11, (h) -SO2R12, and (trifluoromethyl henyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidin yrazinyl, thienyl, or morpholinyl, which is unsubstituted or substituted with 1-substituents where the substituents are independently selected from: (i) -C1-6alkyl, (iii) halo, (iv) hydroxy, and (v) trifluoromethyl (v) trifluoromethyl (v) -O-C1-6alkyl, (v) -O-C1-6alkyl, (v) halo, (v) hydroxy, and (v) trifluoromethyl;		
20	(a) halo, (b) hydroxy, (c) -O-C1-6alkyl, (d) -C3-6cycloalkyl, (e) phenyl, which is unsubstituted or substituted with 1-5 substituents the substituents are independently selected from: (i) -C1-6alkyl, (ii) -O-C1-6alkyl, (iii) halo, (iv) hydroxy, and (v) trifluoromethyl, (f) -CO2R9, (g) -NR10R11, (h) -CONR10R11, (i) -SO2R12, and (j) trifluoromethyl (3) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimi pyrazinyl, thienyl, or morpholinyl, which is unsubstituted wit substituents where the substituents are independently selected from: (a) -C1-6alkyl, (b) -O-C1-6alkyl, (c) halo, (d) hydroxy, and (e) trifluoromethyl; m is 1 or 2; n is 1 or 2; and pharmaceutically acceptable salts thereof and individual enantioners and divisions.	orpholinyl, which is unsubstituted or substituted with 1.5			
		babbi	halo, hydroxy, -O-C1-6alkyl, -C3-6cycloalkyl, phenyl, which is unsubstituted or substituted with 1-5 substituents whe the substituents are independently selected from: (i) -C1-6alkyl, (ii) -O-C1-6alkyl, (iii) halo, (iv) hydroxy, and (v) trifluoromethyl, -CO2R9, -NR10R11, -CONR10R11, -SO2R12, and trifluoromethyl lyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidiny zinyl, thienyl, or morpholinyl, which is unsubstituted or substituted with 1-6 tituents where the substituents are independently selected from: -C1-6alkyl, -O-C1-6alkyl, halo, hydroxy, and trifluoromethyl;		
		(u)			
25					
		(a) halo, (b) hydroxy, (c) -O-C1-6alkyl, (d) -C3-6cycloalkyl, (e) phenyl, which is unsubstituted or substituted with 1-5 substituents the substituents are independently selected from: (i) -C1-6alkyl, (ii) -O-C1-6alkyl, (iii) halo, (iv) hydroxy, and (v) trifluoromethyl, (f) -CO2R9, (g) -NR10R11, (i) -SO2R12, and (j) trifluoromethyl (3) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimi pyrazinyl, thienyl, or morpholinyl, which is unsubstituted wit substituents where the substituents are independently selected from: (a) -C1-6alkyl, (b) -O-C1-6alkyl, (c) halo, (d) hydroxy, and (e) trifluoromethyl; In is 1 or 2; In is 1 or 2; In and pharmaceutically acceptable salts thereof and individual enantioneers and discussions.			
45					
		(e)	trifluoromethyl;		
	m is 1 or 2:				
n					
	•	utically	accentable solto	hamafa 1: 1: 1: 1:	
	thereof.	Juily	cooptable sails [nereor and individual enantiomers and diastereomers	

2. The compound of Claim 1 of the formula:

5

10

15

$$\begin{array}{c|c}
 & O \\
 & N \\
 & A^{1} \\
 & A^{2} \\
 & R^{4}
\end{array}$$

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

3. The compound of Claim 1 of the formula:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

4. The compound of Claim 1 of the formula:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

5. The compound of Claim 1 of the formula:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

6. The compound of Claim 1 of the formula:

5

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

7. The compound of Claim 1, wherein B is selected from:

unsubstituted or substituted with 1-5 substituents selected from R^1 , R^2 , R^{3a} and R^{3b} ,

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

- 8. The compound of Claim 1, wherein B is selected from benzimidazolyl, 2-oxobenzoxazolinyl, 2-oxobenzimidazolinyl, indolyl, 2-oxobenzothiazolinyl, 1,3-dihydro-2*H*-imidazo[4,5-*b*]pyridine-2-one, naphtho[2,1-*d*][1,3]oxazolin-2(3*H*)-one and naphtho[1,2-*d*][1,3]oxazolin-2(1*H*)-one.
- 9. The compound of Claim 1, wherein R¹, R², R^{3a} and R^{3b} are independently selected from:
 - (1) -C₁₋₆alkyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
 - (a) fluoro,

15

20

25

30

- (b) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, or morpholinyl,
- (c) -CO₂R⁹, wherein R⁹ is independently selected from:
 - (i) hydrogen, and
 - (ii) -C₁-6alkyl,
- (d) -CONR10aR11a, wherein R^{10a} and R^{11a} are independently selected from:
 - (i) hydrogen, and
 - (ii) -C₁₋₆alkyl,

or where R10a and R11a may be joined together to form a ring selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, and morpholinyl, and

- (e) -O-C₃₋₆cycloalkyl,
- phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, thienyl, pyridazinyl, pyrrolidinyl, thiazolyl, isothiazolyl, 2-oxopyrrolidinyl, tetrahydrofuryl, piperidinyl, tetrahydrothienyl, or tetrahydrothiopyranyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
 - (a) -C₁-6alkyl, which is unsubstituted or substituted with 1-3 fluoro
 - (b) halo,

-CO₂R⁹, wherein R⁹ is selected from: (c) (i) hydrogen, (ii) -C₁₋₄alkyl, and (iii) -C3-6cycloalkyl, 5 $-(CO)R^9$ (d) -CONR 10aR 11a, wherein R 10a and R 11a are independently selected (e) from: (i) hydrogen, and (ii) -C₁₋₆alkyl, 10 or where R^{10a} and R^{11a} may be joined together to form a ring selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, and morpholinyl, -O-C₁-6alkyl, which is unsubstituted or substituted with 1-3 fluoro, (f) (g) hydroxy, (h) oxo, 15 (i) -S-C₁₋₄alkyl, (j) -S(O)-C₁₋₄alkyl, and (k) -SO₂-C₁₋₄alkyl, (3) halo, (4) hydroxy, 20 -O-C1-6alkyl, which is unsubstituted or substituted with 1-3 fluoro, (5) (6) -NH₂, (7) -C3-6cycloalkyl, -(CO)-(CO)NR10aR11a, wherein R10a and R11a are independently selected (8) from: 25 (a) hydrogen, and -C₁-6alkyl, and (b) (9) -CN. The compound of Claim 1, wherein R¹ and R² are independently selected 10. 30 from: (1) -C1-4alkyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from: (a) fluoro, (b) phenyl,

-CO₂R⁹, wherein R⁹ is independently selected from: (c) (i) hydrogen, and (ii) -C₁₋₄alkyl, -CONR10aR11a, wherein R10a and R11a are independently selected (d) 5 from: (i) hydrogen, and (ii) -C₁₋₄alkyl, or where R10a and R11a may be joined together to form a ring selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, and morpholinyl, 10 and (e) -O-C3-6cycloalkyl, phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, (2) pyrazinyl, thienyl, pyridazinyl, pyrrolidinyl, thiazolyl, tetrahydrofuryl, piperidinyl, or tetrahydrothienyl, which is unsubstituted or substituted with 1-5 substituents 15 where the substituents are independently selected from: -C₁-4alkyl, which is unsubstituted or substituted with 1-3 fluoro (a) (b) halo. -CO₂R⁹, wherein R⁹ is selected from: (c) (i) hydrogen, 20 (ii) -C₁₋₄alkyl, and (iii) -C3-6cycloalkyl, (d) -(CO)R⁹. -CONR 10aR 11a, wherein R 10a and R 11a are independently selected (e) from: 25 (i) hydrogen, and (ii) -C₁₋₄alkyl, -O-C1-4alkyl, which is unsubstituted or substituted with 1-3 fluoro, (f) (g) hydroxy, (h) oxo 30 (i) -S-C₁₋₄alkyl, (j) -S(O)-C₁₋₄alkyl, and -SO₂-C₁₋₄alkyl, (k) (3) halo, (4) hydroxy,

(5) -O-C₁-4alkyl, which is unsubstituted or substituted with 1-3 fluoro,

- (6) $-NH_2$,
- (7) -C₃₋₆cycloalkyl,
- (8) -(CO)-(CO)NR10aR11a, wherein R10a and R11a are independently selected from:
 - (a) hydrogen, and
 - (b) -C₁₋₄alkyl, and
- (9) -CN.

5

15

20

30

11. The compound of Claim 1, wherein R^{3a} and R^{3b} and the carbon atom(s) to which they are attached are joined together to form a ring selected from piperidinyl, cyclohexenyl, cyclohexyl and pyrrolidinyl, which is unsubstituted or substituted with 1-3 substituents independently selected from:

(a) -C₁₋₆alkyl, which is unsubstituted or substituted with 1-3 substituents independently selected from:

- (i) halo, and
- (ii) phenyl,
- (b) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl and pyrazinyl,
- (c) -CO₂R⁹, wherein R⁹ is selected from:
 - (i) hydrogen, and
- (ii) -C₁₋₄alkyl.
- 12. The compound of Claim 1, wherein R^{3a} and R^{3b} and the carbon atom(s) to which they are attached are joined together to form a piperidine ring, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from:
 - (a) -C₁₋₆alkyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from:
 - (i) fluoro, and
 - (ii) phenyl,
 - (b) $-CO_2-C_{1-4}$ alkyl.
 - 13. The compound of Claim 1, wherein R⁴ is selected from: hydrogen and -C₁₋₆alkyl, which is unsubstituted or substituted with fluoro.

14. The compound of Claim 1, wherein R^{5a} , R^{5b} and R^{5c} are independently selected from hydrogen, C_{1-6} alkyl and halo.

5

- 15. The compound of Claim 1, wherein R⁶ is selected from:
- (1) hydrogen,
- (2) -C₁₋₄alkyl which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
 - (a) halo,

(b) hydroxy,

- (c) -C₃-6cycloalkyl, and
- (d) phenyl, and
- phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, or pyrazinyl.


15

10

16. A compound of the formula:

wherein Rb is selected from:

20



and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

5

10

17. A compound of the formula:

wherein Rb is selected from:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

18. A compound of the formula:

wherein Rb is selected from:

-	\mathbb{R}^{b}	
	Me HN O	
	Mé O O O O O O O O O O O O O O O O O O O	
	CI N N	
	MeO N N	
	Me N	
	HO	
	HN-PO	

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

19. The compound of the formula:


5

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

20. A compound of the formula:

wherein Rb is selected from:

5



and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

21. A compound selected from:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

22. A pharmaceutical composition which comprises an inert carrier and the compound of Claim 1.

23. The use of the compound of Claim 1 for the preparation of a medicament useful in the treatment of headache, migraine or cluster headache.